BIOVIC_B fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Biovica International AB is engages in the development and commercialization of novel blood-based biomarker assays to improve the monitoring of modern cancer therapies. It offers DiviTum assay, which is intended to monitor and predict treatment response in cancer patients. The company was founded in 2009 and is headquartered in Uppsala, Sweden.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
BIOVIC_B has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company